New developments in the management of severe skin and deep skin structure infections – focus on tedizolid

References

• McCaigLFMcDonaldLCMandalSJerniganDBStaphylococcus aureus-associated skin and soft tissue infections in ambulatory careEmerg Infect Dis200612111715172317283622
   PubMed Web of Science ®Google Scholar
• PallinDJEganDJPelletierAJEspinolaJAHooperDCCamargoCAJrIncreased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureusAnn Emerg Med200851329129818222564
   PubMed Web of Science ®Google Scholar
• EdelsbergJTanejaCZervosMTrends in US hospital admissions for skin and soft tissue infectionsEmerg Infect Dis20091591516151819788830
   PubMed Web of Science ®Google Scholar
• KachatryanA PDJohnsonKRising US hospital admissions for Gram+ acute bacterial skin and skin structure infections (ABSSSIs)Poster presented at SHMMarch 24–27; 2014Las Vegas, Nevada Available from: http://content.stockpr.com/duratatherapeutics/db/Publications/2134/file/3-13c_SHM_HCUP_Poster.pdfAccessed December 10, 2014
   Google Scholar
• PallinDJEspinolaJALeungDYHooperDCCamargoCAJrEpidemiology of dermatitis and skin infections in United States physicians’ offices, 1993–2005Clin Infect Dis200949690190719663690
   PubMed Web of Science ®Google Scholar
• StevensDLBisnoALChambersHFPractice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of AmericaClin Infect Dis2014592e10e5224973422
   PubMed Web of Science ®Google Scholar
• BraunLCraftDWilliamsRTuamokumoFOttoliniMIncreasing clindamycin resistance among methicillin-resistant Staphylococcus aureus in 57 northeast United States military treatment facilitiesPediatr Infect Dis J200524762262615999004
   PubMed Web of Science ®Google Scholar
• HultenKGKaplanSLGonzalezBEThree-year surveillance of community onset health care-associated staphylococcus aureus infections in childrenPediatr Infect Dis J200625434935316567988
   PubMed Web of Science ®Google Scholar
• BowenACLilliebridgeRATongSYIs Streptococcus pyogenes resistant or susceptible to trimethoprim-sulfamethoxazole?J Clin Microbiol201250124067407223052313
   PubMed Web of Science ®Google Scholar
• BergmannRvan der LindenMChhatwalGSNitsche-SchmitzDPFactors that cause trimethoprim resistance in Streptococcus pyogenesAntimicrob Agents Chemother20145842281228824492367
   PubMed Web of Science ®Google Scholar
• ArbeitRDMakiDTallyFPThe safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infectionsClin Infect Dis200438121673168115227611
   PubMed Web of Science ®Google Scholar
• TalbotGHThyeDDasAGeYPhase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infectionsAntimicrob Agents Chemother200751103612361617682094
   PubMed Web of Science ®Google Scholar
• WilcoxMHTackKJBouzaEComplicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 studyClin Infect Dis200948220321219072714
   PubMed Web of Science ®Google Scholar
• BoucherHWWilcoxMTalbotGHPuttaguntaSDasAFDunneMWOnce-weekly dalbavancin versus daily conventional therapy for skin infectionN Engl J Med2014370232169217924897082
   PubMed Web of Science ®Google Scholar
• CoreyGRKablerHMehraPSingle-dose oritavancin in the treatment of acute bacterial skin infectionsN Engl J Med2014370232180219024897083
   PubMed Web of Science ®Google Scholar
• CoreyGRGoodSJiangHSingle-Dose Oritavancin Versus 7–10 Days of Vancomycin in the Treatment of Gram-Positive Acute Bacterial Skin and Skin Structure Infections: The SOLO II Noninferiority StudyClin Infect Dis201560225426225294250
   PubMed Web of Science ®Google Scholar
• StryjewskiMEGrahamDRWilsonSETelavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organismsClin Infect Dis200846111683169318444791
   PubMed Web of Science ®Google Scholar
• MoranGJFangECoreyGRDasAFDe AndaCProkocimerPTedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trialLancet Infect Dis201414869670524909499
   PubMed Web of Science ®Google Scholar
• MarburyTDowellJASeltzerEBuckwalterMPharmacokinetics of dalbavancin in patients with renal or hepatic impairmentJ Clin Pharmacol200949446547619318696
   PubMed Web of Science ®Google Scholar
• KumarAMannHJKeshtgarpourMIn vitro characterization of oritavancin clearance from human blood by low-flux, high-flux, and continuous renal replacement therapy dialyzersInt J Artif Organs201134111067107422183520
   PubMed Web of Science ®Google Scholar
• BrownSDTraczewskiMMComparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control rangesAntimicrob Agents Chemother20105452063206920231392
   PubMed Web of Science ®Google Scholar
• SainiJSHomeyerNFulleSGohlkeHDeterminants of the species selectivity of oxazolidinone antibiotics targeting the large ribosomal subunitBiol Chem2013394111529154124006327
   PubMed Web of Science ®Google Scholar
• DrydenMSLinezolid pharmacokinetics and pharmacodynamics in clinical treatmentJ Antimicrob Chemother201166Suppl 4iv7iv1521521707
   PubMed Web of Science ®Google Scholar
• FlanaganSPassarellJLuQFiedler-KellyJLudwigEProkocimerPTedizolid population pharmacokinetics, exposure response, and target attainmentAntimicrob Agents Chemother201458116462647025136028
   PubMed Web of Science ®Google Scholar
• FlanaganSDBienPAMunozKAMinassianSLProkocimerPGPharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrugPharmacotherapy201434324025023926058
   PubMed Web of Science ®Google Scholar
• AndesDvan OgtropMLPengJCraigWAIn vivo pharmacodynamics of a new oxazolidinone (linezolid)Antimicrob Agents Chemother200246113484348912384354
   PubMed Web of Science ®Google Scholar
• LodiseTPFangEMinassianSLProkocimerPGPlatelet Profile in Patients with Acute Bacterial Skin and Skin Structure Infections Receiving Tedizolid or Linezolid: Findings from the Phase 3 ESTABLISH Clinical TrialsAntimicrob Agents Chemother201458127198720425246392
   PubMed Web of Science ®Google Scholar
• SchaadtRSweeneyDShinabargerDZurenkoGIn vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agentAntimicrob Agents Chemother20095383236323919528279
   PubMed Web of Science ®Google Scholar
• DrusanoGLLiuWKulawyRLouieAImpact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection modelAntimicrob Agents Chemother201155115300530521911576
   PubMed Web of Science ®Google Scholar
• ShawKJPoppeSSchaadtRIn vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strainsAntimicrob Agents Chemother200852124442444718838596
   PubMed Web of Science ®Google Scholar
• LivermoreDMMushtaqSWarnerMWoodfordNActivity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococciJ Antimicrob Chemother200963471371519164418
   PubMed Web of Science ®Google Scholar
• SahmDFDeaneJBienPAResults of the Surveillance of Tedizolid Activity and Resistance Program: in vitro susceptibility of Gram-positive pathogens collected in 2011 and 2012 from the United States and EuropeDiagn Microbiol Infect Dis201581211211825488274
   PubMed Web of Science ®Google Scholar
• FlanaganSBartizalKMinassianSLFangEProkocimerPIn vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactionsAntimicrob Agents Chemother20135773060306623612197
   PubMed Web of Science ®Google Scholar
• FlanaganSMcKeeEEDasDNonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial functionAntimicrob Agents Chemother201559117818525331703
   PubMed Web of Science ®Google Scholar
• FlanaganSMinassianSLMorrisDPharmacokinetics of tedizolid in subjects with renal or hepatic impairmentAntimicrob Agents Chemother201458116471647625136024
   PubMed Web of Science ®Google Scholar
• OngVFlanaganSFangEAbsorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphateDrug Metab Dispos20144281275128424875463
   PubMed Web of Science ®Google Scholar
• SahreMSabarinathSGrantMSkin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteersInt J Antimicrob Agents2012401515422584101
   PubMed Web of Science ®Google Scholar
• HousmanSTPopeJSRussomannoJPulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteersAntimicrob Agents Chemother20125652627263422330925
   PubMed Web of Science ®Google Scholar
• ProkocimerPDe AndaCFangEMehraPDasATedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trialJAMA2013309655956923403680
   PubMed Web of Science ®Google Scholar
• ProkocimerPBienPSurberJPhase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infectionsAntimicrob Agents Chemother201155258359221115795
   PubMed Web of Science ®Google Scholar
• ProkocimerP BPMuñozKAAsterR2008. Hematological effects of TR-701, linezolid and placebo administered for 21 days in healthy subjectsPoster F1–2069a Abstract presented at: 48th Interscience conference of Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA), 46th Annu. Meet.October 25–28, 2008Washington, DC
   Google Scholar
• WongERabSTedizolid phosphate (sivextro): a second-generation oxazolidinone to treat acute bacterial skin and skin structure infectionsP T201439855557925136252
   PubMedGoogle Scholar
• costco.com [homepage on the Internet]Costco Pharmacy Drug Directory Available from: http://www.costco.com/Pharmacy/drug-directory-main?storeId=10301&catalogId=10701&langId=-1Accessed February 1, 2015
   Google Scholar
• Chase-OrtizMThe Future Deals in the Generic IndustryPresented at: Drug, Chemical and Associated Technologies WeekMarch 15–18, 2010New York City, NY
   Google Scholar
• walmart.com [homepage on the Internet]Walmart Retail Prescription Program Drug List Revised12312013 Available from: http://i.walmart.com/i/if/hmp/fusion/genericdruglist.pdfAccessed February 3, 2015
   Google Scholar
• MillerLGDaumRSCreechCBClindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infectionsN Engl J Med2015372121093110325785967
   PubMed Web of Science ®Google Scholar